The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
1-Deoxynojirimycin inhibits the reaction [Thapsigargin results in increased activity of CASP3 protein]; 1-Deoxynojirimycin inhibits the reaction [Tunicamycin results in increased activity of CASP3 protein]
1-Deoxynojirimycin inhibits the reaction [Thapsigargin results in increased expression of DDIT3 protein]; 1-Deoxynojirimycin inhibits the reaction [Tunicamycin results in increased expression of DDIT3 protein]
[1-Deoxynojirimycin co-treated with Polysaccharides] inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of FBP2 protein]
[1-Deoxynojirimycin co-treated with Polysaccharides] inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of G6PC protein]
[1-Deoxynojirimycin co-treated with Polysaccharides] inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in decreased expression of GCK protein]
[1-Deoxynojirimycin co-treated with Polysaccharides] inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of INSR protein]
[1-Deoxynojirimycin co-treated with Polysaccharides] inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in decreased expression of LPL mRNA]
[1-Deoxynojirimycin co-treated with Polysaccharides] inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of PCX protein]
[1-Deoxynojirimycin co-treated with Polysaccharides] inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of PCK1 protein]
[1-Deoxynojirimycin co-treated with Polysaccharides] inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of PDK1 mRNA]
[1-Deoxynojirimycin co-treated with Polysaccharides] inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in decreased expression of PFKP protein]
[1-Deoxynojirimycin co-treated with Polysaccharides] inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in decreased expression of PKLR protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rb1 results in increased phosphorylation of AKT1 protein]; Fulvestrant inhibits the reaction [ginsenoside Rb1 results in increased phosphorylation of AKT1 protein]; Pertussis Toxin inhibits the reaction [ginsenoside Rb1 results in increased phosphorylation of AKT1 protein]
ginsenoside Rb1 inhibits the reaction [aluminum chloride results in decreased expression of BMP2 mRNA] ginsenoside Rb1 results in increased expression of BMP2 mRNA
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 mRNA]; Cycloheximide inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein]; Dactinomycin inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 mRNA]; Dactinomycin inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein]; fulvestrant inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 mRNA]; fulvestrant inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein]; ginsenoside Rb1 results in increased expression of and results in increased activity of HMOX1 protein; Pertussis Toxin inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 mRNA]; Pertussis Toxin inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein] [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 mRNA; [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 protein
ginsenoside Rb1 inhibits the reaction [aluminum chloride results in decreased expression of IGF1 mRNA] ginsenoside Rb1 results in increased expression of IGF1 mRNA
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rb1 results in increased localization of NFE2L2 protein]; [ginsenoside Rb1 co-treated with ginsenoside 20S-protopanaxatriol] results in increased expression of NFE2L2 protein; fulvestrant inhibits the reaction [ginsenoside Rb1 results in increased localization of NFE2L2 protein]; ginsenoside Rb1 results in increased activity of and results in increased localization of NFE2L2 protein; Pertussis Toxin inhibits the reaction [ginsenoside Rb1 results in increased localization of NFE2L2 protein] ginsenoside Rb1 affects the localization of NFE2L2 protein [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] affects the localization of NFE2L2 protein ginsenoside Rb1 results in increased expression of NFE2L2 mRNA
ginsenoside Rb1 results in increased expression of RUNX2 mRNA ginsenoside Rb1 inhibits the reaction [aluminum chloride results in decreased expression of RUNX2 mRNA]
ginsenoside Rb1 inhibits the reaction [aluminum chloride results in decreased expression of TGFB1 mRNA] ginsenoside Rb1 results in increased expression of TGFB1 mRNA
ginsenoside Rb1 inhibits the reaction [TNFSF11 protein affects the localization of RELA protein]; ginsenoside Rb1 inhibits the reaction [TNFSF11 protein results in increased expression of FOS mRNA]; ginsenoside Rb1 inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 mRNA]; ginsenoside Rb1 inhibits the reaction [TNFSF11 protein results in increased expression of TNF mRNA] ginsenoside Rb1 results in decreased susceptibility to TNFSF11 protein
AHR protein affects the susceptibility to [indirubin-3'-monoxime results in decreased expression of CD86 protein]; AHR protein affects the susceptibility to [indirubin-3'-monoxime results in decreased expression of ITGAX protein] indirubin-3'-monoxime binds to and results in increased activity of AHR protein indirubin-3'-monoxime binds to AHR protein
indirubin-3'-monoxime promotes the reaction [tetraarsenic tetrasulfide results in increased expression of AQP9 mRNA]; indirubin-3'-monoxime promotes the reaction [tetraarsenic tetrasulfide results in increased expression of AQP9 protein]
[Lipopolysaccharides co-treated with indirubin-3'-monoxime] results in decreased expression of CD40 protein; indirubin-3'-monoxime inhibits the reaction [Lipopolysaccharides results in increased expression of CD40 protein] indirubin-3'-monoxime results in decreased expression of CD40 protein
indirubin-3'-monoxime results in increased expression of CD80 protein [Lipopolysaccharides co-treated with indirubin-3'-monoxime] results in increased expression of CD80 protein; indirubin-3'-monoxime promotes the reaction [Lipopolysaccharides results in increased expression of CD80 protein]
[Lipopolysaccharides co-treated with indirubin-3'-monoxime] results in decreased expression of CD86 protein; AHR protein affects the susceptibility to [indirubin-3'-monoxime results in decreased expression of CD86 protein]; indirubin-3'-monoxime inhibits the reaction [Lipopolysaccharides results in increased expression of CD86 protein]
[indirubin-3'-monoxime co-treated with Tetradecanoylphorbol Acetate co-treated with Lipopolysaccharides] results in increased expression of CYP1A1 mRNA; [indirubin-3'-monoxime co-treated with Tetradecanoylphorbol Acetate] results in increased expression of CYP1A1 mRNA; [indirubin-3'-monoxime co-treated with Tetradecanoylphorbol Acetate] results in increased expression of CYP1A1 protein indirubin-3'-monoxime results in increased expression of CYP1A1 mRNA indirubin-3'-monoxime results in increased expression of CYP1A1 protein
[indirubin-3'-monoxime co-treated with Tetradecanoylphorbol Acetate co-treated with Lipopolysaccharides] results in decreased expression of HSPA2 mRNA; [indirubin-3'-monoxime co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of HSPA2 mRNA
[indirubin-3'-monoxime co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of HSPA9 mRNA indirubin-3'-monoxime results in increased expression of HSPA9 mRNA
[Lipopolysaccharides co-treated with indirubin-3'-monoxime] results in decreased expression of ICAM1 protein; indirubin-3'-monoxime inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 protein] indirubin-3'-monoxime results in decreased expression of ICAM1 protein
indirubin-3'-monoxime results in increased expression of IDO1 protein Lipopolysaccharides affects the susceptibility to [indirubin-3'-monoxime results in increased expression of IDO1 protein]
indirubin-3'-monoxime results in increased expression of IDO2 protein Lipopolysaccharides affects the susceptibility to [indirubin-3'-monoxime results in increased expression of IDO2 protein]
[Lipopolysaccharides co-treated with indirubin-3'-monoxime] results in increased secretion of IL10 protein; indirubin-3'-monoxime promotes the reaction [Lipopolysaccharides results in increased secretion of IL10 protein] indirubin-3'-monoxime results in decreased secretion of IL10 protein
[Lipopolysaccharides co-treated with indirubin-3'-monoxime] results in decreased secretion of IL1B protein; indirubin-3'-monoxime inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]
indirubin-3'-monoxime results in decreased expression of IL27 protein Lipopolysaccharides affects the susceptibility to [indirubin-3'-monoxime results in decreased expression of IL27 protein]
[Lipopolysaccharides co-treated with indirubin-3'-monoxime] results in decreased expression of IL6 protein; [Lipopolysaccharides co-treated with indirubin-3'-monoxime] results in decreased secretion of IL6 protein; indirubin-3'-monoxime inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]
AHR protein affects the susceptibility to [indirubin-3'-monoxime results in decreased expression of ITGAX protein]; indirubin-3'-monoxime inhibits the reaction [Lipopolysaccharides results in increased expression of ITGAX protein]
[indirubin-3'-monoxime co-treated with Tetradecanoylphorbol Acetate co-treated with Lipopolysaccharides] results in decreased expression of NFKBIA mRNA
[indirubin-3'-monoxime co-treated with Tetradecanoylphorbol Acetate] results in increased expression of PTGS2 mRNA; [indirubin-3'-monoxime co-treated with Tetradecanoylphorbol Acetate] results in increased expression of PTGS2 protein
[Lipopolysaccharides co-treated with indirubin-3'-monoxime] results in increased activity of RELA protein indirubin-3'-monoxime results in decreased activity of RELA protein
indirubin-3'-monoxime results in increased expression of TGFB2 protein Lipopolysaccharides affects the susceptibility to [indirubin-3'-monoxime results in increased expression of TGFB2 protein]
indirubin-3'-monoxime results in increased expression of TGFB3 protein Lipopolysaccharides affects the susceptibility to [indirubin-3'-monoxime results in increased expression of TGFB3 protein]
[Lipopolysaccharides co-treated with indirubin-3'-monoxime] results in decreased secretion of TNF protein; indirubin-3'-monoxime inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]
benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [miglustat inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [miglustat results in increased activity of CFTR protein mutant form]; Brefeldin A inhibits the reaction [miglustat inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; Brefeldin A inhibits the reaction [miglustat results in increased activity of CFTR protein mutant form]; geldanamycin promotes the reaction [miglustat inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; geldanamycin promotes the reaction [miglustat results in increased activity of CFTR protein mutant form]; miglustat inhibits the reaction [CANX protein binds to CFTR protein mutant form]; miglustat inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]; Thapsigargin promotes the reaction [miglustat inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; Thapsigargin promotes the reaction [miglustat results in increased activity of CFTR protein mutant form]
miglustat inhibits the reaction [[ST8SIA1 protein affects the abundance of Gangliosides] which results in decreased expression of PAWR protein]; miglustat inhibits the reaction [ST8SIA1 protein results in increased expression of BCL2 protein]
[miglustat results in decreased activity of UGCG protein] which results in decreased abundance of Gangliosides; [miglustat results in decreased activity of UGCG protein] which results in decreased abundance of Glucosylceramides
orlistat results in increased activity of CASP3 protein Orlistat inhibits the reaction [Dietary Fats results in increased expression of CASP3 mRNA] orlistat results in increased cleavage of CASP3 protein
orlistat analog results in increased cleavage of and results in increased activity of CASP8 protein; orlistat results in increased cleavage of and results in increased activity of CASP8 protein Orlistat inhibits the reaction [Dietary Fats results in increased expression of CASP8 mRNA]
Orlistat inhibits the reaction [Dietary Fats results in decreased activity of CAT protein]; Orlistat inhibits the reaction [Dietary Fats results in decreased expression of CAT mRNA]; Orlistat inhibits the reaction [Dietary Fats results in decreased expression of CAT protein] Orlistat results in decreased expression of CAT protein
[[orlistat results in decreased abundance of Fatty Acids, Nonesterified] which results in decreased secretion of CCK protein] which results in decreased secretion of PNLIP protein; orlistat inhibits the reaction [Fats results in increased secretion of CCK protein]; orlistat inhibits the reaction [Olive Oil results in increased secretion of CCK protein] orlistat results in decreased secretion of CCK protein
orlistat results in increased phosphorylation of EIF2A protein orlistat promotes the reaction [EIF2AK3 protein results in increased phosphorylation of EIF2A protein] Cycloheximide inhibits the reaction [orlistat results in increased phosphorylation of EIF2A protein] orlistat analog results in increased phosphorylation of EIF2A protein; orlistat results in increased phosphorylation of EIF2A protein
EIF2AK3 gene mutant form results in increased susceptibility to orlistat orlistat promotes the reaction [EIF2AK3 protein results in increased phosphorylation of EIF2A protein]
ERBB2 protein affects the susceptibility to orlistat orlistat affects the localization of ERBB2 protein orlistat results in decreased expression of ERBB2 mRNA; orlistat results in decreased expression of ERBB2 protein
orlistat analog binds to FASN protein Orlistat results in decreased expression of FASN protein orlistat results in decreased activity of FASN protein [orlistat results in decreased activity of FASN protein] which affects the abundance of Fatty Acids, Nonesterified; orlistat inhibits the reaction [FASN protein results in increased chemical synthesis of Palmitic Acid] orlistat analog results in decreased activity of FASN protein; orlistat results in decreased activity of FASN protein [orlistat results in decreased activity of FASN protein] which results in decreased abundance of Fatty Acids; [orlistat results in decreased activity of FASN protein] which results in decreased abundance of Phosphatidylcholines; [orlistat results in decreased activity of FASN protein] which results in decreased abundance of Phosphorylcholine; [orlistat results in decreased activity of FASN protein] which results in decreased chemical synthesis of Fatty Acids; [orlistat results in decreased activity of FASN protein] which results in decreased expression of SKP2 protein; orlistat binds to and results in decreased activity of FASN protein; orlistat inhibits the reaction [FASN protein results in decreased susceptibility to Doxorubicin]; orlistat inhibits the reaction [FASN protein results in decreased susceptibility to Mitoxantrone] FASN protein affects the susceptibility to orlistat
orlistat inhibits the reaction [Dietary Fats results in increased secretion of GCG protein]; orlistat inhibits the reaction [Olive Oil results in increased secretion of GCG protein] orlistat results in decreased secretion of GCG protein orlistat results in decreased expression of GCG protein
orlistat inhibits the reaction [Olive Oil results in decreased expression of GHRL protein]; orlistat inhibits the reaction [Triglycerides results in decreased secretion of GHRL protein]
orlistat inhibits the reaction [[Corn Oil co-treated with (5'-(4-amino-7,7-dimethyl-2-trifluoromethyl-7H-pyrimido(4,5-b)(1,4)oxazin-6-yl)-2',3'-dihydrospiro(cyclohexane-1,1'-inden)-4-yl)acetic acid] results in increased activity of GPT protein]
orlistat results in decreased expression of INS protein orlistat affects the expression of INS protein orlistat results in increased expression of INS protein
orlistat results in decreased activity of LPL protein [orlistat results in decreased activity of LPL protein] which affects the uptake of Triglycerides orlistat inhibits the reaction [[LPL protein results in increased hydrolysis of Triglycerides] which results in increased uptake of Triglycerides]; orlistat inhibits the reaction [LPL protein results in decreased activity of TNF protein]; orlistat inhibits the reaction [very low density lipoprotein triglyceride results in increased activity of LPL protein] orlistat inhibits the reaction [Dietary Fats results in decreased expression of LPL protein]
Orlistat inhibits the reaction [Dietary Fats results in increased expression of NOS2 mRNA]; Orlistat inhibits the reaction [Dietary Fats results in increased expression of NOS2 protein]
Orlistat inhibits the reaction [Fats results in increased secretion of NTS protein]; Orlistat inhibits the reaction [Olive Oil results in increased secretion of NTS protein]
orlistat results in decreased activity of PLA2G7 protein [orlistat co-treated with Ezetimibe] results in decreased activity of PLA2G7 protein; [orlistat co-treated with Fenofibrate] results in decreased activity of PLA2G7 protein
orlistat results in decreased secretion of PNLIP protein [[orlistat results in decreased abundance of Fatty Acids, Nonesterified] which results in decreased secretion of CCK protein] which results in decreased secretion of PNLIP protein; orlistat inhibits the reaction [[PNLIP protein co-treated with CLPS protein] results in increased hydrolysis of Olive Oil] orlistat affects the folding of PNLIP protein orlistat inhibits the reaction [Taurocholic Acid results in increased activity of PNLIP protein] orlistat results in decreased activity of PNLIP protein
orlistat inhibits the reaction [Isoproterenol results in increased phosphorylation of PRKAA1 protein] orlistat inhibits the reaction [1-Methyl-3-isobutylxanthine results in increased phosphorylation of and results in increased activity of PRKAA1 protein]; orlistat inhibits the reaction [Isoproterenol results in increased phosphorylation of and results in increased activity of PRKAA1 protein]
orlistat results in decreased secretion of PYY protein orlistat inhibits the reaction [Olive Oil results in increased expression of PYY protein]; orlistat inhibits the reaction [Triglycerides results in increased secretion of PYY protein]
[orlistat results in decreased activity of FASN protein] which results in decreased expression of SKP2 protein orlistat results in decreased expression of SKP2 protein
orlistat inhibits the reaction [LPL protein results in decreased activity of TNF protein] Orlistat inhibits the reaction [Dietary Fats results in increased expression of TNF mRNA]
resolvin D2 inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; resolvin D2 inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein]
resolvin D2 inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; resolvin D2 inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]
sibutramine results in decreased activity of CYP2B6 protein sibutramine inhibits the reaction [CYP2B6 protein results in increased hydroxylation of Bupropion]
browse the term
